Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
| ▸ | ACLY | P53396 | 1/20 | 0.33 |
| ▸ | HMGCR | P04035 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ACACB | O00763 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26000369 | 0.83 | CYP2D6 (0.32) | CYP2D6TSHRCYP2C19HIF1A | |
| SCHEMBL4831111 | 0.81 | CYP2D6 (0.37) | CYP2D6TSHRCYP2C19HIF1ADGAT1 | |
| SCHEMBL27485689 | 0.79 | TSHR (0.36) | CYP2D6TSHRCYP2C19HIF1ADGAT1 | |
| SCHEMBL9249667 | 0.79 | ALDH1A1 (0.48) | CYP2D6TSHRCYP2C19HIF1ADGAT1 | |
| SCHEMBL667170 | 0.78 | TSHR (0.43) | CYP2D6TSHRCYP2C19HIF1AACLY | |
| SCHEMBL25842795 | 0.77 | DGAT1 (0.50) | CYP2D6TSHRDGAT1HDAC3HDAC1 | |
| SCHEMBL3798958 | 0.77 | CYP2D6 (0.34) | CYP2D6TSHRCYP2C19HIF1ADGAT1 | |
| SCHEMBL189917 | 0.77 | GGT1 (0.41) | CYP2D6TSHRCYP2C19HIF1ADGAT1 | |
| SCHEMBL4553890 | 0.77 | DGAT1 (0.37) | CYP2D6DGAT1HMGCRCHRM1TBXA2R | |
| SCHEMBL28313432 | 0.76 | TSHR (0.37) | CYP2D6TSHRCYP2C19HIF1AACLY |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11814406-B2 | Compounds and methods for treatment of viral infections | GILEAD SCIENCES, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-11787825-B2 | Therapeutic compounds for HIV virus infection | GILEAD SCIENCES, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-20230203069-A1 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | GILEAD SCIENCES, INC. | 2023-06-29 | — | — | US | disclosed |
| US-20230151043-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2023-05-18 | — | — | US | disclosed |
| US-9901571-B2 | Tetrahydropyrazolopyridine derivatives as ghrelin receptor agonists | RAQUALIA PHARMA INC. (JP) | 2018-02-27 | — | — | US | disclosed |
| US-20170304277-A1 | TETRAHYDROPYRAZOLOPYRIDINE DERIVATIVES AS GHRELIN RECEPTOR AGONISTS | RAQUALIA PHARMA INC. (JP) | 2017-10-26 | — | — | US | disclosed |
| US-20170197961-A1 | SERINE DERIVATIVES AS GHRELIN RECEPTOR AGONISTS | RAQUALIA PHARMA INC. (JP) | 2017-07-13 | — | — | US | disclosed |
| US-9227995-B2 | Peptides | Jacobsen, Øyvind (NO) | 2016-01-05 | — | — | US | disclosed |
| US-9145415-B2 | Nitrogen-containing heterocyclic compound or salt thereof | FUJIFILM CORPORATION (JP) | 2015-09-29 | — | — | US | disclosed |
| US-9073830-B2 | Compound for inhibiting 11β-hydroxy steroid dehydrogenase 1, and a pharmaceutical composition comprising the same | HYUNDAI PHARM CO., LTD. (KR) | 2015-07-07 | — | — | US | disclosed |
| US-9005815-B2 | Negative active material for rechargeable lithium battery, method of preparing same, and rechargeable lithium battery | SAMSUNG SDI CO., LTD. (KR) | 2015-04-14 | — | — | US | disclosed |
| US-20150045339-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND OR SALT THEREOF | FUJIFILM CORPORATION (JP) | 2015-02-12 | — | — | US | disclosed |
| US-20140206875-A1 | A COMPOUND FOR INHIBITING 11B-HYDROXY STEROID DEHYDROGENASE 1, AND A PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | HYUNDAI PHARM CO., LTD. (KR) | 2014-07-24 | — | — | US | disclosed |
| US-8674144-B2 | Catalyst for asymmetric hydrogenation and method for manufacturing optically active carbonyl compound using the same | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2014-03-18 | — | — | US | disclosed |
| US-8653080-B2 | Methods for screening and compounds that protect against amyloid diseases | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2014-02-18 | — | — | US | disclosed |
| US-8552205-B2 | Derivatives of 6,7-dihydro-5H-imidazo[1,2-alpha]imidazole-3-carboxylic acid amides | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-10-08 | — | — | US | disclosed |
| US-20120136176-A1 | CATALYST FOR ASYMMETRIC HYDROGENATION AND METHOD FOR MANUFACTURING OPTICALLY ACTIVE CARBONYL COMPOUND USING THE SAME | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2012-05-31 | — | — | US | disclosed |
| US-20110263479-A1 | Peptides | UNIVERSITETET I OSLO (NO) | 2011-10-27 | — | — | US | disclosed |
| US-20110224188-A1 | DERIVATIVES OF 6,7-DIHYDRO-5H-IMIDAZO[1,2-alpha]IMIDAZOLE-3-CARBOXYLIC ACID AMIDES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-09-15 | — | — | US | disclosed |
| US-20040220186-A1 | PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease | PFIZER INC. | 2004-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224188-A1 | DERIVATIVES OF 6,7-DIHYDRO-5H-IMIDAZO[1,2-alpha]IMIDAZOLE-3-CARBOXYLIC ACID AMIDES | HPGDS, COL14A1, ARG1 | CYP2D6 2705/4885TSHR 4087/4885CYP2C19 3328/4885 |
| US-20170304277-A1 | TETRAHYDROPYRAZOLOPYRIDINE DERIVATIVES AS GHRELIN RECEPTOR AGONISTS | GHSR, GHRHR, GIPR | CYP2D6 2397/4885TSHR 27/4885CYP2C19 2485/4885 |
| US-20150045339-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND OR SALT THEREOF | FLT3, NPM1, ABL1 | CYP2D6 4151/4885TSHR 3784/4885CYP2C19 1976/4885 |
| US-20120136176-A1 | CATALYST FOR ASYMMETRIC HYDROGENATION AND METHOD FOR MANUFACTURING OPTICALLY ACTIVE CARBONYL COMPOUND USING THE SAME | HMOX1, HIRA, HRH1 | CYP2D6 1270/4885TSHR 4664/4885CYP2C19 2242/4885 |
| US-20170197961-A1 | SERINE DERIVATIVES AS GHRELIN RECEPTOR AGONISTS | GHSR, GHRHR, GIPR | CYP2D6 4503/4885TSHR 31/4885CYP2C19 4368/4885 |
| US-11814406-B2 | Compounds and methods for treatment of viral infections | HAVCR2, EIF2AK2, ACE | CYP2D6 1594/4885TSHR 4452/4885CYP2C19 2652/4885 |
| US-20140206875-A1 | A COMPOUND FOR INHIBITING 11B-HYDROXY STEROID DEHYDROGENASE 1, AND A PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | HSD11B1, HSD11B2, HSD17B1 | CYP2D6 179/4885TSHR 4194/4885CYP2C19 87/4885 |
| US-20110263479-A1 | Peptides | VIP, NGLY1, NPPA | CYP2D6 4856/4885TSHR 811/4885CYP2C19 4790/4885 |
| US-20230151043-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | HAVCR2, EIF2AK2, ACE | CYP2D6 1594/4885TSHR 4452/4885CYP2C19 2652/4885 |
| US-11787825-B2 | Therapeutic compounds for HIV virus infection | HAVCR2, MAVS, CD4 | CYP2D6 2283/4885TSHR 4874/4885CYP2C19 2952/4885 |
| US-20040220186-A1 | PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease | PDE9A, PDE2A, PDE12 | CYP2D6 645/4885TSHR 3079/4885CYP2C19 104/4885 |
| US-20230203069-A1 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | HAVCR2, MAVS, CD4 | CYP2D6 2283/4885TSHR 4874/4885CYP2C19 2952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.